ReNeuron is a UK based Proprietary Stem Cell and Exosome Technologies company, harnessing its unique stem cell technologies to develop ‘off the shelf’ treatments for disease with significant unmet needs.

The Company’s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. The Company has also out-licensed its CTX programme in stroke disability to Fosun in China.

ReNeuron’s stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com